Compare Hut 8 Corp (HUT) vs Novavax Inc (NVAX) Price & Performance

HUT trades at $84.27, down 5.63% today, with a bearish technical outlook despite oversold RSI readings. The company reported negative earnings in recent quarters, missing expectations, with a net income margin of -188.59% for 2026. Recent positive developments include securing a $1.07 billion credit facility and analyst optimism around AI infrastructure contracts.

While analyst consensus is strongly bullish with a $162.69 price target, significant execution risks persist given negative profitability and cash flow challenges. The stock offers high potential upside if AI infrastructure contracts materialize but carries substantial risk from ongoing losses and competitive pressures in the digital infrastructure space.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.